Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan.

Slides:

Advertisements

Similar presentations

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

G. Lucchini on behalf of the EBMT PDWP SCT in pediatric AML in 1CR: does the conditioning regimen matter? Scientific Day 12 th May, 2016 London.

Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life Carina Venter, BSc, Brett Pereira, MRCP, Jane.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

What drives prescription patterns in pediatric asthma management?

Risk of an asthma exacerbation after bariatric surgery in adults

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life Carina Venter, BSc, Brett Pereira, MRCP, Jane.

Fatty acids, inflammation, and asthma

Advances in food allergy in 2015

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Long-term immune reconstitution after matched unrelated hematopoietic stem cell transplantation for immunodeficiency Vy Hong-Diep Kim, MD, Brenda Reid,

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Fatty acids, inflammation, and asthma

Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency Justin Wahlstrom,

One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years Reem Ahmed Elfeky, MD, Juliana M. Furtado-Silva,

Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency Evelina Mazzolari, MD, Concetta.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series Mirjam E. Belderbos, MD, PhD, Andrew R. Gennery,

Gut microbiome variations during hematopoietic stem cell transplant in severe combined immunodeficiency Jonathan P. Lane, MBBS, Christopher J. Stewart,

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Treatment of chronic autoimmune urticaria with omalizumab

Allogeneic Haematopoietic Stem Cell Transplantation for Systemic Onset Juvenile Idiopathic Arthritis Juliana Silva, MD, Julie Glanville, Fani Ladomenou,

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience Mary A.

Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies Rebecca A. Marsh, MD, Kyle M. Hebert,

Cats and dogs and the risk of atopy in childhood and adulthood

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Infection with a respiratory virus before hematopoietic cell transplantation is associated with alloimmune-mediated lung syndromes Birgitta Versluys,

Food allergy in patients with primary immunodeficiency diseases: Prevalence within the US Immunodeficiency Network (USIDNET) Karen S. Tuano, MD, Jordan.

What are the best outcome measurements for atopic eczema

Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency Amel Hassan,

What is an “eosinophilic phenotype” of asthma?

T-cell receptor αβ+ and CD19+ cell–depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency Ravi M.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Higher incidence of pediatric anaphylaxis in northern areas of the United States William J. Sheehan, MD, Dionne Graham, PhD, Lin Ma, MS, Sachin Baxi,

Advances in the approach to the patient with food allergy

A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children Felicia A. Rabito, PhD, MPH, John C. Carlson,

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Risk of oral food challenges

Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Eosinophilic esophagitis treated with immunotherapy to dust mites

Reply Journal of Allergy and Clinical Immunology

Usa Tantibhaedhyangkul, MD, Carla M. Davis, MD, Lenora M

Measles and immunomodulation

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists Michael Schatz, MD, MS, Christine.

Caroline C. Horner, MD, MSCI, Courtney Dula, MS, Leonard B

Environmental factors and eosinophilic esophagitis

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts Helen Chapel, MA,

Safety and efficacy of repeated monthly carboplatin desensitization

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Liver disease predicts mortality in patients with X-linked immunodeficiency with hyper- IgM but can be prevented by early hematopoietic stem cell transplantation

Presentation transcript:

Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen Kanchan Rao, MRCPCH, MNAMS, Stuart Adams, PhD, Waseem Qasim, MD, PhD, Zoe Allwood, BSc, MPH, Austen Worth, MRCP, MD, PhD, Juliana Silva, MD, Giovanna Lucchini, MD, Robert Chiesa, MD, Paul Veys, FRCP, FRCPath, Persis Amrolia, PhD, FRCP, FRCPath Journal of Allergy and Clinical Immunology Volume 138, Issue 4, Pages 1152-1160 (October 2016) DOI: 10.1016/j.jaci.2016.01.053 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Lineage-specific chimerism in the BM and PBSC groups. Chimerism in the T-cell (T) and myeloid lineage (M) at 1 month, 6 months, and 1 year after HSCT and at last follow-up in the BM and PBSC groups is shown. At all time points, the incidence of MC was higher in the BM group than in the PBSC group, especially in the myeloid lineage. At last follow-up, the incidence of very low-level MC in the myeloid lineage of the BM group was 26% compared with 8% in the PBSC group. *In case of second transplantation or DLI, chimerism immediately before the second procedure is represented here. Journal of Allergy and Clinical Immunology 2016 138, 1152-1160DOI: (10.1016/j.jaci.2016.01.053) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Chimerism according to donor source at last follow-up. A, With BM as the stem cell source, mMUDs had a 40% incidence of very low-level MC, which was most evident in the myeloid lineage. B, With PBSCs as the stem cell source, 100% of mismatched donors achieved complete donor chimerism in all lineages. MSDs also had a 30% incidence of very low-level MC in the myeloid lineage of the BM group. M, Myeloid engraftment; T, T-cell engraftment. Journal of Allergy and Clinical Immunology 2016 138, 1152-1160DOI: (10.1016/j.jaci.2016.01.053) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 GVHD after BM and PBSC transplantations. Incidence of significant (grade II or greater), severe aGVHD (grade III and IV), and cGVHD was low with BM transplants. There was a significantly higher incidence of aGVHD and cGVHD with PBSC transplants from mismatched donors. The incidence of GVHD with PBSC transplants from matched donors was low and similar to that in the BM group. The incidence of severe GVHD was only 4% in the matched PBSC setting. Journal of Allergy and Clinical Immunology 2016 138, 1152-1160DOI: (10.1016/j.jaci.2016.01.053) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 A-C, Overall survival in the BM and PBSC groups, event-free survival in patients with less than 10% donor chimerism compared with patients with greater than 10% donor chimerism, and survival according to donor type are shown. Survival was very good in the BM and PBSC groups at 76% and 84%, respectively. There was no statistical difference in survival according to donor type. Patients with less than 10% donor chimerism had significantly poorer event-free survival at only 25% compared with 70% in patients with higher levels of chimerism. Journal of Allergy and Clinical Immunology 2016 138, 1152-1160DOI: (10.1016/j.jaci.2016.01.053) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions